Tonix Pharmaceuticals Holding has been granted a patent for a method of manufacturing a eutectic of Cyclobenzaprine HCl and ß-mannitol. The composition comprises specific percentages of the two components and involves mixing or milling them together. GlobalData’s report on Tonix Pharmaceuticals Holding gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Tonix Pharmaceuticals Holding, Cancer treatment biomarkers was a key innovation area identified from patents. Tonix Pharmaceuticals Holding's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for eutectic of cyclobenzaprine hcl and mannitol
A recently granted patent (Publication Number: US11839594B2) discloses a method for manufacturing a eutectic of Cyclobenzaprine HCl and ß-mannitol with specific composition percentages. The method involves mixing Cyclobenzaprine HCl and ß-mannitol or milling them together to achieve a composition of 75%±2% Cyclobenzaprine HCl and 25±2% ß-mannitol by weight.
The patent further details the manufacturing process, including options for milling the components together or mixing them via compression. The method specifies the use of a high shear granulator for milling or roller compaction for compression. Additionally, the patent mentions the use of micronized Cyclobenzaprine HCl in the process, providing a comprehensive guide for producing the desired eutectic composition.
To know more about GlobalData’s detailed insights on Tonix Pharmaceuticals Holding, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.